Highly rated in
Highly rated in
Check Dr. Heather A. Jacene's experience treating your condition:
About Dr. Heather A. Jacene

Heather Jacene is a Nuclear Medicine specialist and a Radiologist in Boston, Massachusetts. Jacene has been practicing medicine for over 22 years and is highly rated in 5 conditions, according to our data. Her top areas of expertise are Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET), WT1-Related Wilms Tumor Syndromes, and Renal Cell Carcinoma (RCC). She is licensed to treat patients in Massachusetts and Maryland. Jacene is currently accepting new patients.

Her clinical research consists of co-authoring 99 peer reviewed articles and participating in 7 clinical trials in the past 15 years.


MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Heather A. Jacene it is best to call her office and ask if your insurance is accepted.

Accepts Medicare

Dr. Heather A. Jacene accepts the following insurance:

  •  Ambetter

Call to see if your plan is accepted.
1153 Centre St, Boston, MA 02130
Other Locations
75 Francis St, Boston, MA 02115
450 Brookline Ave, Boston, MA 02215
Background & Education
Graduate Institution
Rutgers R W Johnson Medical School (Cam/new Bruns/pisc), 2001
Nuclear Medicine
Nuclear Medicine in MA
Hospital Affiliations
Brigham And Womens Hospital
Dana Farber Cancer Institute
Brigham And Womens Faulkner Hospital
Languages Spoken
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase I Trial of Triapine and Lutetium Lu 177 Dotatate in Combination for Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
FDG PET to Assess Therapeutic Response in Patients With Bone-Dominant Metastatic Breast Cancer, FEATURE
A Pilot Study of 18Fluorine-Fluciclovine Positron Emission Tomography/Computed Tomography for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy
A Phase I/II Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma
A Phase 1/2 Multi-Center, Safety and Efficacy Study Evaluating Intravenously Administered 131I-TM601 in Patients With Progressive and/or Recurrent Malignant Glioma
View 4 Less Clinical Trials -

99 Total Publications

Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer.

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
Learn about our expert tiers
Learn more
Similar Doctors